Biliary tract cancer drug granted orphan drug designation in US

The US regulator has granted biliary tract cancer therapy Silmitasertib orphan drug designation.

There are currently no treatments for this rare cancer, and the US food and Drug Administration (FDA) hopes that pharmaceutical firm Senhwa’s drug will meet the significant need for new biliary tract cancer options.